1. Auflage - Juli 2010
199,- Euro
2010. XLVI, 1204 Seiten, Softcover
171 Abb. (30 Farbabb.), 127 Tab. 
- Handbuch/Nachschlagewerk -
ISBN-10: 3-527-32902-1
ISBN-13: 978-3-527-32902-1 - Wiley-VCH, Weinheim

Preis inkl. Mehrwertsteuer zzgl. Versandkosten.





Inhalt



Kurzbeschreibung
Now as softcover edition! The most comprehensive reference source for the development, production and therapeutic application of antibodies. A must-have resource for academic researchers, decision makers in industry and healthcare professionals in the clinic.

Aus dem Inhalt
Section I: Technologies
Foreword
A Greeting from the Editor
PART 0: INTRODUCTION
Therapeutic Antibodies - From Past to Future
PART I: SELECTING AND SHAPING THE ANTIBODY MOLECULE
Selection strategies I: Monoclonal Antibodies
Selection strategies II: Antibody Phage Display
Selection strategies III: Transgenic Mice
Bioinformatic Tools for Antibody Engineering
Molecular Engineering I: Humanization
Molecular Engineering II: Affinity Maturation
Molecular Engineering III: Fc Engineering
PART II: THE WAY INTO THE CLINIC
Production and Downstream Processing
Pharmaceutical Formulation and Clinical Application
Immunogenicity of Antibody Therapeutics
Regulatory Considerations
Intellectual Property Issues

Section II: Emerging Developments
PART III: BEYOND IGG: MODIFIED ANTIBODIES
Immunoscintigraphy and Radioimmunotherapy
Bispecific Antibodies
Immunotoxins / Targeted RNases
PART IV: EMERGING CONCEPTS
Automation of Selection and Engineering
Emerging Technologies for Antibody Selection
Emerging Alternative Production Systems
Non-Antibody Scaffolds
Emerging Therapeutic Concepts I: ADEPT
Emerging Therapeutic Concepts II: Nanotechnology
Emerging Therapeutic Concepts III:Cell-bound antibodies
Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies
PART V: ONGOING CLINICAL STUDIES:
Antibodies in Phase I/II/III: Cancer Therapy
Antibodies in Phase I/II/III: Targeting TNF

Section III: APPROVED THERAPEUTICS
Adalimumab (Humira)
Alemtuzumab (Mabcampath)
Bevacizumab (Avastin)
Cetuximab (Erbitux)
Efalizumab (Raptiva)
Fanolesomab/Technetium99m (Neutrospec)
Gemtuzumab Ozogamicin (Mylotarg)
Infliximab (Remicade)
Muromonab (Orthoclone)
Natalizumab (Tysabri)
Omalizumab (Xolair)
Palivizumab (Synagis)
Rituximab (Rituxan)
Trastuzumab (Herceptin)
Overview: Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab, Edrecolomab, Igovomab, Nofetumomab, Satumomab, Sulesomab, Tositumomab and Votumumab
Yttrium-90 Ibritumomab Tiuxetan (Zevalin)